To the full analysis
Cardinal Health stock: growth
CAHCardinal Health reported $254.25B in revenue for fiscal 2026, up 14.2% on the prior year, up 9.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.8%
per year from 2007 to 2026, per share 8.7%
Earnings (Annual rate)
−0.6%
per year from 2007 to 2026, per share 2.1%
Free cash flow (Annual rate)
9.1%
per year from 2007 to 2026, per share 12.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 9.4% | 7.7% | 5.8% |
| Revenue per share | 14.1% | 11.2% | 8.7% |
| Earnings | 22.9% | 1.8% | −0.6% |
| Earnings per share | 28.3% | 5.2% | 2.1% |
| Free cash flow | 17.4% | 6.1% | 9.1% |
| Free cash flow per share | 22.5% | 9.6% | 12.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $86.85B | $1.93B | $865.7M |
| 2008 | $87.41B | $1.3B | $1.14B |
| 2009 | $95.99B | $1.15B | $1.03B |
| 2010 | $98.5B | $642.2M | $1.88B |
| 2011 | $102.64B | $959M | $1.1B |
| 2012 | $107.55B | $1.07B | $913M |
| 2013 | $101.09B | $334M | $1.53B |
| 2014 | $91.08B | $1.17B | $2.28B |
| 2015 | $102.53B | $1.22B | $2.24B |
| 2016 | $121.55B | $1.43B | $2.51B |
| 2017 | $129.98B | $1.29B | $797M |
| 2018 | $136.81B | $256M | $2.38B |
| 2019 | $145.53B | $1.36B | $2.39B |
| 2020 | $152.92B | −$3.69B | $1.59B |
| 2021 | $162.47B | $611M | $2.03B |
| 2022 | $181.33B | −$938M | $2.74B |
| 2023 | $204.98B | $330M | $2.36B |
| 2024 | $226.83B | $852M | $3.25B |
| 2025 | $222.58B | $1.56B | $1.85B |
| 2026 | $254.25B | $1.71B | $4.53B |
Revenue by segment
How Cardinal Health, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Pharmaceutical Member92%
- Gmpd5%
- Other3%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|
| Pharmaceutical Member | $210.02B | $204.64B | $234.83B | 92.4% |
| Gmpd | $12.38B | $12.64B | $12.72B | 5% |
| Other | $4.43B | $5.3B | $6.7B | 2.6% |
| Total revenue | $226.83B | $222.58B | $254.25B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jan 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.